logo
As class action trial looms, Meta and Flo could face 'mind-boggling' damages

As class action trial looms, Meta and Flo could face 'mind-boggling' damages

Reuters21 hours ago
July 15 (Reuters) - It's hard to imagine more intimate queries than those that fertility tracking app Flo allegedly asked its users. Among them: When was your last period? How often do you have sex? Masturbate? Do you get yeast infections?
As app maker Flo Health and co-defendant Meta are set to face a class action trial in San Francisco federal court next week for allegedly violating the privacy of millions of Flo users, the question now is whether the companies will cut a deal or risk what Flo on appeal, opens new tab termed "mind-boggling" damages.
Litigators sometimes bandy about the phrase 'bet-the-company case,' but this could be the real thing. Facebook parent Meta is defending against claims of violating the California Invasion of Privacy Act, which carries statutory penalties of $5,000 per violation.
That would add up to at least $190 billion in damages if, as plaintiffs have previously suggested, opens new tab, there are 38 million class members. If each app entry is treated as a separate violation, total damages could be quadrillions of dollars — "a sum so large it may as well be infinite," as Flo put it.
A spokesperson for Meta, which is represented by outside counsel from Latham & Watkins and Gibson, Dunn & Crutcher, said the plaintiffs' claims against the company "are simply false, and we are confident that the evidence at trial will demonstrate the realities."
Flo, represented by Dechert, separately is dealing with claims including violations of California's Confidentiality of Medical Information Act, which carries penalties of $1,000 per violation. A spokesperson for the London-based, privately held company said Flo "is committed to protecting the privacy of its users, and any allegation otherwise has no merit."
The companies have argued that Flo's privacy disclosures gave users notice of the alleged misconduct and that they impliedly consented, that the shared data did not contain personally identifying information and that Meta never 'intended' to intercept communications.
According to the Meta spokesperson, the company does 'not want health or other sensitive information' and its terms 'prohibit developers from sending any.'
Google, which was also named in the suit, reached a settlement in principle last week on as-yet undisclosed terms. A Google spokesperson did not respond to my request for comment.
Given the risk of outsized verdicts (even those that don't involve 16 figures), class actions rarely go to trial. For example, Google last month took a chance on one involving cellular phone data, only to be hit with a $314 million verdict by a California jury on July 1.
The Flo plaintiffs invoke California's 1967 invasion of privacy law, a Cold War relic that makes it illegal to covertly eavesdrop or record telephone conversations. As I previously wrote, the cause of action has enjoyed a resurgence of late among plaintiffs' lawyers, especially in connection with the use of chatbots, tracking pixels and other data analytics software.
The Flo jury trial, set for July 21 before U.S. District Judge James Donato, looms as current and former Meta leaders face an $8 billion shareholder suit in Delaware that kicks off Wednesday. The shareholders allege Meta executives violated a 2012 agreement between Facebook and the Federal Trade Commission to protect users' data, my Reuters colleague Tom Hals reports.
The Flo class action also has its roots in an FTC case. The agency sued Flo, opens new tab after The Wall Street Journal in 2019 reported that it was able to intercept identifying health information about Flo users transmitted by the app to Facebook.
The FTC's 2021 settlement required Flo to obtain users' consent before sharing their health information and to notify affected women about the disclosure.
According to the follow-on class action, opens new tab, which covers all Flo app users nationwide from Nov. 1, 2016, to Feb. 28, 2019, plus a California subclass, Flo integrated code from Meta and Google's software development kits, which are used for data analytics, into its app. That allegedly allowed the companies to review personal information on users' menstrual cycles, sex lives and pregnancies, despite promises by Flo that the data would remain confidential.
The third parties were "were free to use this data for their own purposes," including marketing and advertising, the complaint alleges. "If Plaintiff and Class members had known that Flo Health would share their intimate health data, they would not have used the Flo App."
Plaintiffs' lawyers from Labaton Keller Sucharow; Lowey Dannenberg and Spector Roseman & Kodroff did not respond to requests for comment.
Donato certified the class in May, writing, opens new tab that the 'loss of control over one's personal information' is a concrete harm, "whether from stealing access to a personal diary in 1916 or obtaining user information in a healthcare app in 2016.'
The decision prompted an interlocutory appeal, opens new tab in June by Flo to the 9th U.S. Circuit Court of Appeals. Flo argued that Donato wrongly held that the company's class action waiver was unenforceable. The judge deemed the provision unconscionable because it was buried in Flo's terms of service.
Flo also argued that the company's use of the software development kits is 'a practice as unremarkable as it is widespread,' and that it disclosed using the kits in its privacy policy and terms of service. Flo also said the transmitted data was de-identified, consisting of alphanumeric strings corresponding to the device on which the app was used.
The appeals court in six-sentence order, opens new tab on June 17 denied Flo's petition and declined to stay the lower court proceedings.
'Cases of this magnitude almost never proceed to trial,' Flo noted in its appeal, describing the 'hydraulic pressure' to settle.
I can only imagine. But if it does indeed go to trial, all I can say is, pass the popcorn.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Researchers try new ways of preserving more hearts for transplants
Researchers try new ways of preserving more hearts for transplants

The Independent

time18 minutes ago

  • The Independent

Researchers try new ways of preserving more hearts for transplants

Two university hospitals are pioneering new ways to expand lifesaving heart transplants for adults and babies — advances that could help recover would-be heart donations that too often go unused. The new research aims to overcome barriers for using organs from someone who dies when their heart stops. Called DCD, or donation after circulatory death, it involves a controversial recovery technique or the use of expensive machines. Surgeons at Duke and Vanderbilt universities reported Wednesday that they've separately devised simpler approaches to retrieve those hearts. In the New England Journal of Medicine, they described successfully transplanting hearts to a 3-month-old infant at Duke and three men at Vanderbilt. 'These DCD hearts work just as well as hearts from brain-dead donors,' said Vanderbilt lead author Dr. Aaron M. Williams. How hearts are saved for donation Most transplanted hearts come from donors who are brain dead. In those situations, the body is left on a ventilator that keeps the heart beating until the organs are removed. Circulatory death occurs when someone has a nonsurvivable brain injury but because all brain function hasn't ceased, the family decides to withdraw life support and the heart stops. That means organs can spend a while without oxygen before being recovered, a time lag usually doable for kidneys and other organs but that can raise questions about the quality of hearts. To counter damage and determine whether DCD organs are usable, surgeons can pump blood and oxygen to the deceased donor's abdominal and chest organs — after clamping off access to the brain. But it's ethically controversial to artificially restore circulation even temporarily and some hospitals prohibit that technique, called normothermic regional perfusion, or NRP. Another option is to 'reanimate' DCD organs in a machine that pumps blood and nutrients on the way to the transplant hospital. The machines are expensive and complex, and Duke's Dr. Joseph Turek said the devices can't be used for young children's small hearts — the age group with the most dire need. New ways of preserving hearts Turek's team found a middle ground: Remove the heart and attach some tubes of oxygen and blood to briefly assess its ability to function — not in a machine but on a sterile table in the operating room. They practiced with piglets. Then came the real test. At another hospital, life support was about to be withdrawn from a 1-month-old whose family wanted to donate — and who would be a good match for a 3-month-old Duke patient in desperate need of a new heart. The other hospital didn't allow the controversial NRP recovery technique but let Turek's team test the experimental alternative. It took just five minutes to tell 'the coronary arteries are filling well, it's pink, it's beating,' Turek said. The team promptly put the little heart on ice and raced it back to Duke. Vanderbilt's system is even simpler: Infuse the heart with a nutrient-rich, cold preservative solution before removing it from the donor's body, similar to how hearts from brain-dead donors are handled. That 'replenishes the nutrients that are depleted during the dying process and helps protect it for transport,' Williams explained, adding that Vanderbilt has performed about 25 such transplants so far. 'Our view is you don't necessarily need to reanimate the heart.' More donated hearts are needed There's a huge need for more transplantable hearts. Hundreds of thousands of adults suffer from advanced heart failure, yet many are never even offered a transplant because of the organ shortage. Every year about 700 children in the U.S. are added to the transplant list for a new heart and about 20% die waiting. Turek said infants are at particular risk. Last year, people whose lives ended via circulatory death made up 43% of the nation's deceased donors — but just 793 of the 4,572 heart transplants. That's why many specialists say finding ways to use more of those hearts is crucial. The new studies are small and early-stage but promising, said Brendan Parent of NYU Langone Health, who directs transplant ethics and policy research. ' Innovation to find ways to recover organs successfully after circulatory death are essential for reducing the organ shortage,' he said. If alternatives pan out, 'I absolutely think that cardiac programs will be thrilled, especially at hospitals that have rejected NRP.' ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

Wall Street banks cash in on market turmoil sparked by Donald Trump's tariff wars
Wall Street banks cash in on market turmoil sparked by Donald Trump's tariff wars

Daily Mail​

time19 minutes ago

  • Daily Mail​

Wall Street banks cash in on market turmoil sparked by Donald Trump's tariff wars

Wall Street's banks have cashed in on the turmoil triggered by Donald Trump's tariff wars. Profits at Goldman Sachs rose by a fifth in the second quarter to £2.8billion as traders put in a record performance. Morgan Stanley reported a 15 per cent rise in income to £2.6billion as wealthy clients 'bought the dip' as markets tumbled on the back of Trump's trade war before rebounding. And Bank of America beat profit estimates, driven by tumultuous markets that helped its traders bring in more revenue.

Trading Day: Trump-Powell drama sizzles, dollar fizzles
Trading Day: Trump-Powell drama sizzles, dollar fizzles

Reuters

time19 minutes ago

  • Reuters

Trading Day: Trump-Powell drama sizzles, dollar fizzles

ORLANDO, Florida, July 16 (Reuters) - TRADING DAY Making sense of the forces driving global markets By Jamie McGeever, Markets Columnist A dramatic day on Wednesday ended with Wall Street in the green and the dollar and short-dated Treasury yields lower, although off their earlier extremes, after President Donald Trump denied reports he will soon fire Fed Chair Jerome Powell. More on that below. In my column today I look at Trump's call for 300 basis points of Fed rate cuts and, although it is wishful thinking, why it shines a light on whether Fed policy is too tight, too loose, or maybe just about right. If you have more time to read, here are a few articles I recommend to help you make sense of what happened in markets today. Today's Key Market Moves Trump-Powell drama sizzles, dollar fizzles At around midday in the U.S. session on Wednesday, it looked like six months of verbal attacks on Fed Chair Jerome Powell from President Donald Trump for not cutting interest rates were about to reach boiling point - according to Bloomberg News, Powell would soon be fired. The market reaction was what you might expect - the dollar, stocks, and short-dated Treasury yields fell, and the yield curve steepened. The most notable moves were in the dollar and two-year yield. But Trump swiftly denied the report, insisting that although he had discussed ousting Powell with lawmakers, it was "highly unlikely" he would fire him. Markets recovered their poise, especially stocks, although the rebound in short-dated yields and the dollar was less pronounced. Trump firing Powell would be a monumental event as no president has ever formally dismissed a Fed Chair. But it would come as little surprise. Trump's desire for lower interest rates is ferocious, and he regularly berates Powell for not cutting them. Political interference in monetary policymaking? Yes, but Trump crossed that Rubicon some time ago. Rates traders still expect no change from the Fed on rates later this month and a quarter point cut by October. They added around 10 bps of expected easing into next year's forecasts. Even at the depths of the selloff on Wednesday Wall Street's main indices were never down more than 1%, perhaps reflecting investors' skepticism that Trump really will pull the trigger. But it's noteworthy given that the S&P 500 and Nasdaq had clocked new highs the day before - there's scope for a deep correction if investors want one. The latest twist in the Trump-Powell saga dominated the U.S. session and will likely be the main driver of global markets again on Thursday. But investors have other signposts to guide them, including corporate earnings, tariffs and economic data. On Wednesday, three of America's biggest banks reported results - Bank of America, Morgan Stanley and Goldman Sachs. On Thursday the spotlight turns to Netflix, and before that in Asia, Taiwan's TSMC, the world's main producer of advanced AI chips. Trump boxes in Fed with extreme rate cut calls While almost no one thinks Donald Trump's verbal attacks on Federal Reserve Chair Jerome Powell are a positive development, they have electrified the debate about whether the U.S. president is right that interest rates are too high. Presidential tirades aside, there is a strong case to be made that the fed funds rate should be lower than its current 4.25-4.50% target range. The labor market is beginning to show signs of cracking, 'hard' economic data is softening, and a tariff-led slowdown may be in the offing. On the other hand, economic growth is clocking in at an annualized pace of around 2.5% and not expected to dip much below 2% next year, unemployment is still historically low, the stock market is at a record peak, and other financial assets like bitcoin have also never been higher. And, crucially, core inflation is still almost a percentage point above the Fed's 2% target, suggesting that we may be starting to see the inflationary impact of tariffs. By those measures, policy may be too loose, not too tight. Indeed, Jason Thomas, head of global research and investment strategy at Carlyle, reckons financial conditions are "unusually accommodative", and argues that had the Fed not said in December that policy was 'restrictive', there would be no need to explain why it hadn't cut rates six months later. The president clearly does not agree. Trump is clamoring for borrowing costs to be slashed by 300 basis points. That would take the policy rate closer to 1%, a level usually associated with severe financial market stress, strong disinflationary pressures or a deep economic funk. Or all three. One would be hard-pressed to find many experts who would agree with Trump's call, even those who fall on the dovish side. But then where should rates be? Policymakers typically use forward-looking models and frameworks to inform their decisions. The most famous of these, so-called 'R-Star', comes in for a lot of criticism, as it is theoretical, referring to the inflation-adjusted long-term neutral interest rate that neither accelerates nor slows growth when inflation is at target. This may be a fuzzy concept, but officials look at it, so investors cannot dismiss it completely. There are two benchmark 'R-Star' models, both partly created by New York Fed President John Williams. One currently puts this rate at around 0.80% and the other around 1.35%. If inflation were at the Fed's target 2%, then these models would put the nominal fed funds rate at around 2.80% or 3.35%, respectively. Fed policymakers split the difference in their latest median projections, putting the long-term nominal Fed funds rate right at 3.00%. If these estimates are anywhere close to accurate, the nominal policy target range of 4.25-4.50% now appears to be restrictive, so the path ahead is lower. Rates traders and investors seem to agree. While the latest CPI report has caused jitters at the long end of the yield curve, rates markets are still pricing in more than 100 basis points of easing over the next 18 months. But this has helped fuel the asset price rally, which, ironically, strengthens the argument that policy may be closer to neutral than models suggest. Powell may have backed the Fed into a corner by maintaining that policy is still restrictive, albeit "modestly" so. These claims signal the Fed will lower rates, but it has not done so, as it is waiting to see if Trump's protectionist trade agenda unleashes inflation. Moreover, it also does not want to appear to be responding to political pressure to cut rates. "Some will say this collision was unavoidable. But the Fed would find itself in a far more defensible position had it embraced a posture of neutrality, pledging to cut or hike as warranted by future developments (including policy shifts)," Carlyle's Thomas wrote on Tuesday. In short, the Fed is in a bit of a bind, and Trump's attacks will only make it worse. His call for 300 basis points of rate cuts may end up being similar to his 'reciprocal tariff' gambit: aim extremely high, settle for something less, and claim victory. The problem, of course, is that monetary policy is not supposed to be a negotiation. What could move markets tomorrow? Want to receive Trading Day in your inbox every weekday morning? Sign up for my newsletter here. Opinions expressed are those of the author. They do not reflect the views of Reuters News, which, under the Trust Principles, opens new tab, is committed to integrity, independence, and freedom from bias.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store